CompletedNot Applicable

Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Germany666 participantsStarted 2020-06-30

Plain-language summary

This study is designed to gain real-world clinical data on the peri- and post-procedural usage of anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation (NVAF) undergoing successful percutaneous coronary intervention (PCI) treated with edoxaban.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥ 18 years of age * Providing written informed consent (ICF) for participation in the study * NVAF treated with edoxaban * Successful PCI * No planned elective cardiac intervention for the whole duration of the study (up to 1 year) * Capability of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year) * Availability of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year) * Willingness of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year) * Not simultaneously participating in any interventional study * Life expectancy \> 1 year Exclusion Criteria: * Not applicable

What they're measuring

Usage of Peri- and Post-procedural Anticoagulation and Antiplatelet Therapy in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Timeframe: Up to 1 year follow up after PCI

Trial details

NCT IDNCT04519944

SponsorDaiichi Sankyo

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-07-06

View on ClinicalTrials.gov More Non-valvular Atrial Fibrillation trials